miRagen Therapeutics Appoints Kevin Koch, Ph.D., to Its Board of Directors

September 9, 2016

BOULDER, CO – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, today announced the appointment of Kevin Koch, Ph.D., to the Company's Board of Directors. Dr. Koch is a Venture Partner with OrbiMed Advisors, LLC, and brings more than 20 years of drug discovery, translational medicine and clinical development expertise to the Company.

"I'm thrilled to welcome Kevin to the miRagen Board," said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics. "He is a seasoned biopharmaceutical executive with a broad range of experience in drug discovery and development, and we believe his insights will be of tremendous benefit to the Company as we move forward."

"I believe that miRagen has built a drug discovery engine for the creation of first-in-class, microRNA-based therapeutics," said Dr. Koch. "I'm delighted to join this team as we transition these innovative medicines into the clinic."

Before joining OrbiMed Advisors, LLC, Dr. Koch was the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen where he managed global drug discovery and biomarker development, as well as the immunology and hematology teams. From 1998-2013, Dr. Koch served as the President, Chief Scientific Officer, Board member and Co-Founder of Array BioPharma, Inc. While there, he built a fully-integrated R&D team that oversaw the invention of over 20 clinical development candidates in multiple therapeutic areas. Prior to Array, Dr. Koch held senior positions at Amgen Inc. and Pfizer Central Research. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, and his Ph.D. in Organic Chemistry from University of Rochester.

Concurrent with this new appointment, Marvin H. Caruthers, Ph.D., is leaving the Board of Directors and is joining the Company's Scientific Advisory Board. "I want to thank Marvin for his important contributions to our success, both scientifically and strategically," said Dr. Marshall. "We look forward to his continued guidance as a Scientific Advisory Board member."

About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need. The Company's lead product candidate, MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155 is currently being studied in a Phase 1 clinical trial in patients suffering from cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides (MF) sub-type. miRagen is also conducting a Phase 1 clinical trial of MRG-201, the Company's lead anti-fibrosis product candidate and a synthetic microRNA mimic (promiR) to microRNA-29b, in human volunteers. miRagen seeks to leverage in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance promising technologies and high-potential product candidates for its own pipeline and in conjunction with strategic collaborators.

About MRG-106 and microRNA-155

MRG-106 is an antimiR (antagonist) of microRNA-155. In hematological malignancy microRNA-155 has key roles in the differentiation, function and proliferation of blood and lymph cells. miRagen believes therapeutic inhibition (antagonism) of microRNA-155 in lymphoma cells may restore normal function and reduce the aberrant cell proliferation that is characteristic of cancerous cells.

About MRG-201 and microRNA-29
MRG-201 is a promiR (agonist) to microRNA-29b. The microRNA-29 family is a well-established negative regulator of a wide variety of genes important in extracellular matrix deposition. The expression of the three family members is consistently down-regulated in a number of pathological fibrotic conditions, including cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis. miRagen believes that numerous studies in cell-culture and genetic replacement in rodents demonstrate the potential of miR-29 normalization to correct many drivers of pathological fibrosis.

For more information, please visit www.miragenrx.com.

For information on clinical trials please visit www.clinicaltrials.gov.

Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the role of microRNAs in disease processes and as potential drug products, the potential for MRG-106 and MRG-201 to target diseases, the adequacy of the Company's capital to support its future operations and the Company's ability to successfully initiate and complete clinical trials. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; and, the impact of competitive products and technological changes. The Company disclaims any intent or obligation to update these forward-looking statements.

Contact:
Christopher J. Morl
Chief Operating Officer
(720) 407-4598
cmorl@miragenrx.com